Intelligence · Clinical Development
Pipeline search results
Programs matching “non-small-cell-lung-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 211 pipeline programs matching "non-small-cell-lung-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
TAK-788
Takeda
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
TGRX-326
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
TNG260
Tango Therapeutics
Non Small Cell Lung Cancer
1 trial -
TNG456
Tango Therapeutics
Non Small Cell Lung Cancer
1 trial -
Toripalimab
Yongchang Zhang
Advanced Non Small Cell Lung Cancer
1 trial -
Trilaciclib
The First People's Hospital of Lianyungang
Advanced Squamous Non-Small-Cell Lung Cancer
1 trial -
Trilaciclib and Sacituzumab Tirumotecan
The First People's Hospital of Lianyungang
NSCLC (Advanced Non-small Cell Lung Cancer)
1 trial -
Ubamatamab
Regeneron UK Limited
Advanced/Metastatic Non-Small Cell Lung Cancer
1 trial -
VATS
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
Zanidatamab
Jazz Pharmaceuticals Ireland Limited
Non-Small Cell Lung Cancer
1 trial -
anlotinib combined with penpulimab
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
befotertinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
NSCLC (Non-small Cell Lung Cancer)
1 trial -
donor-derived NK cell infusion
Chongqing Precision Biotech Co., Ltd
Non-small Cell Lung Cancer
1 trial -
eribulin mesylate + erlotinib
Eisai Co.,
Non-small Cell Lung Cancer
1 trial -
erlotinib [Tarceva]
Hoffmann-La Roche
Non-Small Cell Lung Cancer
1 trial -
furmonertinib
Sun Yat-sen University
Non-small Cell Lung Cancer Metastatic
1 trial -
nanoparticle albumin-bound paclitaxel/carboplatin
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
neratinib
PUMA BIOTECHNOLOGY, INC.
HER2-mutant Non-Small Cell Lung Cancer
1 trial -
osimertinib mesylate tablets and anlotinib hydrochloride capsules
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial -
pembrolizumab
The First People's Hospital of Lianyungang
Advanced Non-squamous Non-small-cell Lung Cancer
1 trial -
silevertinib (BDTX-1535) monotherapy
Blackmores Limited
Non-Small Cell Lung Cancer
1 trial -
ALX2004
ALX ONCOLOGY HOLDINGS INC
NSCLC (Advanced Non-small Cell Lung Cancer)
1 trial -
Atovaquone Oral Suspension
United Therapeutics Europe Ltd
Locally Advanced Non-Small Cell Lung Cancer
1 trial -
BBO-11818
BridgeBio Oncology Therapeutics
Non-Small Cell Lung Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.